Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL.

Proposed period of release:
15/01/2020 to 07/12/2022

Name of the Institute(s) or Company(ies)
Novartis Farmacéutica, S.A. Spain, ;

3. Is the same GMO release planned elsewhere in the Community?
Austria; Germany; France; Italy;

Has the same GMO been notified elsewhere by the same notifier?

If yes, notification number(s):

GMO characterization

GMO is a:
Other: mammal

Identity of the GMO:
Autologous T cells transduced with a replication-deficient HIV-1 derived viral vector to express a chimeric (murine/human) antigen receptor (CAR).

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known